Chinese hamster ovary (CHO) cells are the predominant host cell for production of recombinant biopharmaceutical manufacturing. Biotherapeutics or biologics, encompass any therapeutic derived from biological sources. The global biologics market in 2024 was valued at $458 billion, with monoclonal antibodies (mAbs) comprising the largest segment at ~$263 billion. CHO cell lines have become the work horse for biotherapeutic manufacturing due to several key advantages. Their ability to grow in suspension culture using serum-free, chemically-defined media, combined with robust selection/amplification expression systems and their capacity to perform 'human-like' post-translational modifications (PTMs), has solidified their role in the manufacture of life-changing medicines.